Fig. 3: LSC-Exo prevents the entry of SARS-CoV-2 pseudovirus.
From: Inhalation of ACE2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2
a Biolayer interferometry assay of the binding LSC-Exo or HEK-Exo or rhACE2 to RBD. The left panel was created with Biorender.com. b ELISA analysis of the binding affinity between rhACE2 with RBD in the presence of LSC-Exo or HEK-Exo. n = 3. c Schematic depiction of cell-based neutralization assay, created with Biorender.com. d SARS-CoV-2 WA1 pseudovirus neutralization analysis of LSC-Exo, HEK-Exo, or rhACE2 in A549 cells expressing ACE2, determined by GFP fluorescence intensity. n = 3. e The neutralization potency of LSC-Exo determined by SARS-CoV-2 WA1 pseudovirus neutralization analysis. n = 3. f Flow plots of SARS-CoV-2 WA1 pseudovirus-infected A549 cells that inhibited by LSC-Exo, HEK-Exo, or rhACE2 and its corresponding quantification analysis. n = 3. Gating strategy was shown in Fig. S20b. g Animal study design of the protection of LSC-Exo against SARS-CoV-2 WA1 pseudovirus with a GFP reporter, created with Biorender.com. h Ex-vivo imaging and quantification analysis of lung from mice inoculated with SARS-CoV-2 WA1 pseudovirus. n = 3. i Immunostaining images of whole lung of mice for DAPI (blue), phalloidin (red), and SARS-CoV-2 WA1 pseudovirus (green). Scale bar: 50 μm. Quantification analysis of GFP reporter signals in trachea/bronchioles (j) and parenchyma (k). n = 10 images from 5 hamsters. Data are mean ± s.d. Statistical analysis was performed by two-way ANOVA with Tukey’s multiple comparisons (d) or one-way ANOVA with Bonferroni correction (f, h, j, k). Source data are provided as a Source Data file.
